Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences (NASDAQ:AURA), a clinical-stage biotech developing precision therapies for solid tumors, will participate in two May 2026 investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aura Biosciences (NASDAQ:AURA), a clinical-stage biotech developing precision therapies for solid tumors, will participate in two May 2026 investor conferences.
Management will host fireside chats at the H.C. Wainwright BioConnect Conference and the TD Cowen Oncology Innovation Summit, with live webcasts and 90-day replays on the company’s investor website.
Details
News Market Reaction – AURA
On May 13, the first trading day after this news, AURA closed 1.13% above the previous close.
Data tracked by StockTitan Argus for the May 13 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:
- H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026.
Fireside Chat at 12:00 p.m. ET
- TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026.
Fireside Chat at 1:30 p.m. ET
The live webcasts of the fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Aura’s lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura is headquartered in Boston, MA. Aura’s mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
For more information, visit aurabiosciences.com. Follow us on X, @AuraBiosciences, and visit us on LinkedIn.
Investor and Media Relations Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.